Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) announced that it has been notified by the U.S. Department of Health and Human Services (HHS) office of the Assistant Secretary for Preparedness and Response (ASPR) and Biomedical Advanced Research and Development Authority (BARDA) that pending a decision regarding the outcome of a recently completed In Process Review (IPR) of the Company’s contract for the development of laninamivir octanoate, ASPR/BARDA has issued a Stop-Work Order notifying the Company to discontinue work on a number of activities under its contract. Biota Pharmaceuticals Inc (NASDAQ:BOTA) shares after opening at $3.85 moved to $4.43 on last trade day and at the end of the day closed at $3.68. Company price to sales ratio in past twelve months was calculated as 2.45 and price to cash ratio as 2.51. Biota Pharmaceuticals Inc (NASDAQ:BOTA) showed a negative weekly performance of -38.56%.
Trinity Biotech plc (ADR) (NASDAQ:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, announced results for the quarter ended March 31, 2014.Quarter 1 Results, Total revenues for Q1, 2014 were $25.0m which compares to $20.3m in Q1, 2013, an increase of 23%. Point-Of-Care revenues for Q1, 2014 decreased by 5% when compared to Q1, 2013. HIV sales in the USA were slightly up compared with the comparative period, thus arresting the decline in recent quarters due to the lower availability of federal funding. This reflects the initial impact of Trinity’s recent FDA approval for a claim for HIV-2 on its Uni-gold product. Meanwhile, sales in Africa were lower, reflecting the fact that African sales tend to fluctuate significantly quarter on quarter. Trinity Biotech plc (ADR) (NASDAQ:TRIB) shares fell -0.32% in last trading session and ended the day on $24.70. TRIB return on equity ratio is recorded as 5.40% and its return on assets is 4.50%. Trinity Biotech plc (ADR) (NASDAQ:TRIB) yearly performance is 58.23%.
ICON PLC (NASDAQ:ICLR) plummeted -7.43% after the stock got downgraded by the contributors at Zacks from OutPerform to Neutral. ICON public limited company (ICON), is a contract research organization (CRO), providing outsourced development services on a global basis to the pharmaceutical, biotechnology and medical device industries. The Company specializes in the strategic development, management and analysis of programs, which support all stages of the clinical development process, which include from compound selection to Phase I-IV clinical studies.ICON PLC (NASDAQ:ICLR) shares moved down -2.07% in last trading session and was closed at $38.70, while trading in range of $ 38.57 – 39.84. ICON PLC (NASDAQ:ICLR) year to date (YTD) performance is -4.26%.
Cubist Pharmaceuticals (NASDAQ:CBST)‘s stock had its “neutral” rating restated by Zacks in a research report issued on Friday, American Banking & Market News reports. They currently have a $70.00 price target on the stock. Zacks‘s target price suggests a potential upside of 12.34% from the company’s current price. Cubist Pharmaceuticals Inc (NASDAQ:CBST) weekly performance is 2.80%. On last trading day company shares ended up $70.11. Cubist Pharmaceuticals Inc (NASDAQ:CBST) distance from 50-day simple moving average (SMA50) is -3.83%. Analysts mean target price for the company is $81.56.